Neuropore Therapies

Executive Summary

Neuropore Therapies is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapeutics that modify the progression of neurodegenerative diseases, with a primary focus on Parkinson's disease and related disorders. Founded in 2005 and headquartered in San Diego, the company leverages its expertise in targeting protein misfolding and aggregation—key pathological hallmarks of neurodegeneration. Although Neuropore has not disclosed specific financial details or pipeline status publicly, its long-standing presence in the field suggests a sustained research effort. The company's approach aims to address the underlying causes of disease rather than just symptoms, potentially offering disease-modifying benefits. With no disclosed clinical trial results or regulatory milestones, the company remains a relatively low-profile player in the competitive neurodegenerative disease space. However, its focus on small molecules and established biology could yield meaningful advances if its therapeutic candidates progress through clinical development.

Upcoming Catalysts (preview)

• Q2 2027Phase 1/2a Clinical Trial Data Readout for Lead Candidate in Parkinson's Disease20% success
• Q4 2026IND Submission for a Novel Compound Targeting Alzheimer's Disease15% success
• Q3 2026Strategic Partnership or Licensing Deal for its Platform Technology10% success